Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$16.98
-2.1%		$16.26
$7.78
▼
$34.10
$254.67M1.46111,705 shs175,415 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$10.79
+1.2%		$12.92
$6.62
▼
$15.35
$1.02B1.35939,208 shs820,035 shs
ODTX
Odyssey Therapeutics
$20.73
+1.5%		$22.73
$15.10
▼
$29.05
$981.37MN/A400,755 shs192,502 shs
Savara Inc. stock logo
SVRA
Savara
$4.81
-4.8%		$5.38
$3.34
▼
$7.01
$1.04B0.21.96 million shs2.65 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-3.88%-4.14%+15.59%-21.14%+71.61%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-3.09%-3.53%-24.88%-23.42%+28.90%
ODTX
Odyssey Therapeutics
-8.10%+2.46%-16.65%+21.55%+2,041,999,900.00%
Savara Inc. stock logo
SVRA
Savara
-2.13%-0.39%-5.61%-18.81%+42.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$16.98
-2.1%		$16.26
$7.78
▼
$34.10
$254.67M1.46111,705 shs175,415 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$10.79
+1.2%		$12.92
$6.62
▼
$15.35
$1.02B1.35939,208 shs820,035 shs
ODTX
Odyssey Therapeutics
$20.73
+1.5%		$22.73
$15.10
▼
$29.05
$981.37MN/A400,755 shs192,502 shs
Savara Inc. stock logo
SVRA
Savara
$4.81
-4.8%		$5.38
$3.34
▼
$7.01
$1.04B0.21.96 million shs2.65 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-3.88%-4.14%+15.59%-21.14%+71.61%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-3.09%-3.53%-24.88%-23.42%+28.90%
ODTX
Odyssey Therapeutics
-8.10%+2.46%-16.65%+21.55%+2,041,999,900.00%
Savara Inc. stock logo
SVRA
Savara
-2.13%-0.39%-5.61%-18.81%+42.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.00
Hold$69.00306.36% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.78
Moderate Buy$24.71129.05% Upside
ODTX
Odyssey Therapeutics
2.63
Moderate Buy$35.7572.46% Upside
Savara Inc. stock logo
SVRA
Savara
2.88
Moderate Buy$10.00107.90% Upside

Current Analyst Ratings Breakdown

Latest GLSI, MGTX, ODTX, and SVRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$16.00
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$16.00
9/22/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Hold (C)
9/11/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/14/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$26.00 ➝ $27.00
8/13/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/12/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/11/2026
ODTX
Odyssey Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.03 per shareN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M12.73N/AN/A($0.07) per share-154.14
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.54N/AN/AN/AN/A-793.81%-295.32%11/13/2026 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.7115.20N/AN/A19.87%283.85%29.39%11/12/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$6.77N/AN/AN/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
-$118.84M-$0.58N/AN/AN/AN/A-90.28%-68.95%11/11/2026 (Estimated)

Latest GLSI, MGTX, ODTX, and SVRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.4583$1.71+$2.1683$1.71$0.70 million$321.43 million
8/11/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.27+$0.06-$0.27N/AN/A
8/11/2026Q2 2026
Savara Inc. stock logo
SVRA
Savara
-$0.1413-$0.16-$0.0188-$0.16$2.00 millionN/A
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.54
1.54
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.46
3.76
3.76
ODTX
Odyssey Therapeutics
N/A
11.36
11.36
Savara Inc. stock logo
SVRA
Savara
0.21
10.13
10.13

Institutional Ownership

CompanyInstitutional Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
ODTX
Odyssey Therapeutics
N/A
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
ODTX
Odyssey Therapeutics
N/A
Savara Inc. stock logo
SVRA
Savara
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1314.68 million7.12 millionNot Optionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
39396.04 million88.94 millionOptionable
ODTX
Odyssey Therapeutics
10048.06 millionN/AN/A
Savara Inc. stock logo
SVRA
Savara
70205.46 million194.57 millionOptionable

Recent News About These Companies

Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why
October 2 at 3:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-savara-nasdaq-svra-stock-falls-54-heres-why-2026-10-02/
Bank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRA
September 30 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-520356-shares-of-savara-inc-svra-2026-09-30/
Savara (NASDAQ:SVRA) Stock Rating Raised to Hold at Wall Street Zen
September 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051400
Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-savara-nasdaq-svra-raised-to-hold-at-wall-street-zen-2026-09-26/
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?
September 24, 2026  |  rttnews.comhttps://www.rttnews.com/3693699/savara-awaits-fda-verdict-will-molbreevi-pass-regulatory-muster.aspx
Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-savara-inc-nasdaq-svra-given-consensus-rating-of-moderate-buy-by-analysts-2026-09-18/
Bank of New York Mellon Corp Acquires New Shares in Savara Inc. $SVRA
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-acquires-new-shares-in-savara-inc-svra-2026-09-08/
Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-invests-288-million-in-savara-inc-svra-2026-09-03/
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...
August 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-encore-presentations-results-200500773.html
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
August 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260824428528/en/savara-announces-encore-presentations-of-results-from-the-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-at-the-european-respiratory-society-ers-congress-2026/
Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SVRA/press-releases/
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026  |  caledonianrecord.comC
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930599-savara-high-potential-binary-bet-cruising-to-pdufa-after-3-month-speed-bump
Savara (SVRA) Gets a Buy from Piper Sandler
July 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/3422910/savara-svra-gets-a-buy-from-piper-sandler/
Here's Why You Should Add Savara Stock to Your Portfolio Now
July 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2957995/here-s-why-you-should-add-savara-stock-to-your-portfolio-now?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2957995
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
June 27, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/27/what-savara-investors-should-know-about-this-580-187-option-exercise-and-fda-timeline/
What Is Driving Attention Toward Savara’s Rare Disease Strategy?
June 15, 2026  |  kalkinemedia.comK
Savara Announces New Employment Inducement Grant
June 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260612214793/en/savara-announces-new-employment-inducement-grant/
Savara Announces Chief Financial and Administrative Officer Transition
June 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260608876987/en/savara-announces-chief-financial-and-administrative-officer-transition/
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
June 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/assessing-savara-svra-valuation-shares-171334905.html
Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)
June 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/2303559/oppenheimer-sticks-to-their-buy-rating-for-savara-svra/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$16.98 -0.37 (-2.13%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$17.25 +0.27 (+1.60%)
As of 10/2/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$10.79 +0.13 (+1.22%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$10.82 +0.03 (+0.30%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Odyssey Therapeutics NASDAQ:ODTX

$20.73 +0.31 (+1.52%)
As of 10/2/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Savara stock logo

Savara NASDAQ:SVRA

$4.81 -0.24 (-4.75%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.85 +0.04 (+0.83%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas